Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity

• Published in: Thrombosis Journal 2021-08, Vol.19 (1), p.59-59, Article 59
• Main Authors: Fard, Mahin Behzadi, Fard, Samaneh Behzadi, Ramazi, Shahin, Atashi, Amir, Eslamifar, Zahra
• Format: Article
• Language: English
• Subjects: Acute respiratory distress syndrome; Blood clot; Coronaviruses; COVID-19; Cytokines; Glycoproteins; Health aspects; Heart attack; Immunoglobulins; Infections; Lectins; Ligands; Monoclonal antibodies; Neutrophils; PAMPs; Pathogens; Platelet activation; Proteins; Review; RNA; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Thrombosis; TLRs; Tumor necrosis factor-TNF; Viral infections; Viruses
• ISSN: 1477-9560; 1477-9560
• DOI: 10.1186/s12959-021-00311-9

Thrombosis plays an important role in the Coronavrus Disease 2019 (COVID-19) infection-related complications such as acute respiratory distress syndrome and myocardial infarction. Multiple factors such as oxygen demand injuries, endothelial cells injury related to infection, and plaque formation. Platelets obtained from the patients may have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, showing that the increased activation potential recommends platelet can be hyper-activated in severely ill SARS-CoV-2 cases. Platelets contain multiple receptors that interact with specific ligands. Pathogen's receptors such as Toll-like receptors (TLRs), NOD-like receptor, C-type lectin receptor family, glycoprotein (GP) such as GPαIIbβ3 and GPIbα which allow pathogens to interact with platelets. Platelet TLRs and NOD2 are involved in platelet activation and thrombosis. Accordingly, TLRs are critical receptors that could recognize various endogenous damage-associated molecular patterns and exogenous pathogen-associated molecular patterns (PAMPs). TLRs are considered as important components in the activation of innate immunity response against pathogenic and non-pathogenic components like damaged tissues. TLRs-1,-2,-4,-6,-7 expression on or within platelets has been reported previously. Various PAMPs were indicated to be capable of binding to platelet-TLRs and inducing both the activation and promotion of downstream proinflammatory signaling cascade. It is possible that the increased TLRs expression and TLR-mediated platelets activation during COVID-19 may enhance vascular and coronary thrombosis. It may be hypothesized using TLRs antagonist and monoclonal antibody against P-selectin, as the marker of leukocyte recruitment and platelet activation, besides viral therapy provide therapeutic advances in fighting against the thrombosis related complications in COVID-19.